PUMA BIOTECHNOLOGY (PBYI) Stock: Buy, Sell, or Hold?
PBYI - PUMA BIOTECHNOLOGY INC
$11.02
-0.24 (-2.13%)
▼
5d:
+12.11%
30d:
+12.22%
90d:
+37.92%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
11d
Get Alerted When PBYI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PBYI shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PBYI shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.35
Based on -16.2% avg growth
INTRINSIC VALUE TODAY
$1.46
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBYI is currently trading at $11.02, which is considered extended relative to its 30-day fair value range of $9.47 to $10.48. From a valuation perspective, the stock is trading at a premium (Forward PE: 31.5) compared to its historical average (17.5). At these levels, the market is pricing in 21.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $9.74, while resistance sits at $11.50.
Market Sentiment: PBYI scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $6.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $9.74, while resistance sits at $11.50.
Market Sentiment: PBYI scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $6.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.47 -
$10.48
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
30.0%
All Signals
- BEARISH: Price extended above range (+5.2% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 45.6% above Wall St target ($6.00)
- NEUTRAL: Trading at premium valuation - market expects 21.7% growth which is achievable
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.47 -
$10.48
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.55
(14.1%)
Support & Resistance Levels
Support Level
$9.74
Resistance Level
$11.50
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.49
Wall Street Target
$6.00
(-45.6%)
Revenue Growth (YoY)
7.8%
Earnings Growth (YoY)
35.8%
Profit Margin
11.6%
Valuation Premium vs History
+21.7% premium
PE vs Historical
31.5 vs 17.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+21.7%
(market-implied from PE analysis)
1-Year Target
$13.41
(+22%)
2-Year Target
$16.32
(+48%)
3-Year Target
$19.86
(+80%)
3-Yr Target (if PE normalizes)
(PE: 31→18)
PE COMPRESSION
$11.04
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.5, Growth: -36.4%)
$8.03
(+-27%)
Base:
(SPY PE: 19.9, Growth: -36.4%)
$5.07
(-54%)
Bear:
(PE: 16.9, Growth: -36.4%)
$4.31
(-61%)
📈
Valuation based on Current Earnings
Trailing PE: 21.25 | Current EPS (TTM): $0.53
Bull Case
$8.18
(-26%)
Analyst growth -34.0%, PE expands to 23.4
Base Case
$7.44
(-33%)
Market implied -34.0%, PE stable at 21.3
Bear Case
$7.66
(-31%)
Severe decline -20.0%, PE contracts to 18.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 24, 2026 12:44 AM ET
Data refreshes hourly during market hours. Next update: 1:44 AM
Data refreshes hourly during market hours. Next update: 1:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBYI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 50 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 48 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 43 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$37 | 59 HOLD |
